A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators aimed to assess Jia Wei Yang He Formula as a plus therapy in the treatment of persistent asthma and to explore Airway Microbiome variation of Asthma by Traditional Chinese Medicine treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on the Treatment of Bronchial Asthma With Traditional Chinese Medicine

NCT02937207

Bronchial Asthma

UNKNOWN PHASE2

REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma)

NCT06373692

Bronchial Asthma

NOT_YET_RECRUITING

Effectiveness of Chinese Herbal Therapy for Asthma

NCT00712296

Asthma

TERMINATED PHASE1/PHASE2

Efficacy Study of Acupoint Sticking in Summer to Treat Asthma

NCT02580942

Asthma

COMPLETED NA

TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease

NCT07295938

Mycobacterium Abscessus Pulmonary Disease

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Asthma is a common chronic inflammatory respiratory disease, patients showed high airway reactivity, and the clinical manifestations of recurrent wheezing, shortness of breath, chest tightness or cough with wheezing dyspnea mainly for a breath. Although many studies have shown that viral infections may be an important cause of asthma seasonal attacks. However, more and more studies have shown that bacterial infection is an important risk factor for asthma. Haemophilus influenzae, Moraxella Mora bacteria infection may increase the risk of asthma by a research report.

Chinese medicine decoction, as a common treatment for asthma, can significantly alleviate seasonal attacks and reduce the number of acute attacks. Research shows that Chinese medicine has widely immunomodulatory effects and imbalance of immune system in patients with asthma control, improve the cellular immunity of patients with airway and defense function, significantly reduced asthma attacks of which induced by upper airway infection or chronic persist asthma.

This study will be conducted for 4 weeks of standard anti-asthma treatment plus Jia Wei Yang He Formula for patients.Some patients are not willing to use standard treatment such as inhaled corticosteroids and long-acting β-adrenoceptor agonists because of side effects. We will provide these patients free JWYH formula after the efficacy of the JWYH is validated and the subsequent results are considered exploratory.

Participants will undergo a physical examination, lung function, blood and sputum collection and all induced sputum samples will be detected by 16S ribosomal RNA (16S rRNA) sequencing and analyzed for microbial bioinformatics. To study whether there is association between the efficacy of Jia Wei Yang He Formula and the changes in microbiota composition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchial Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

All treatment group received a standard anti-asthma treatment plus Jia Wei Yang He Formula on study entry, and the control group received Jia Wei Yang He Formula placebo instead.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

This is a Double-blind Trial

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.

Group Type PLACEBO_COMPARATOR

Jia Wei Yang He granule Placebo

Intervention Type DRUG

Made from 1/20 doses which has certain taste, but no therapeutic effect

High dose Treatment Group

Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.

Group Type EXPERIMENTAL

Jia Wei Yang He granule

Intervention Type DRUG

This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time

Low dose Treatment Group

Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.

Group Type EXPERIMENTAL

Jia Wei Yang He granule

Intervention Type DRUG

This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Jia Wei Yang He granule

This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time

Intervention Type DRUG

Jia Wei Yang He granule Placebo

Made from 1/20 doses which has certain taste, but no therapeutic effect

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jia Wei Yang He Formula Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient diagnosed with chronic persistent asthma
* Annual uncontrollable time ≥ 3 months
* Patients who have given written informed consent

Exclusion Criteria

* History of upper upper/lower respiratory infection in the previous 1 months
* History of long-term controller medication use for asthma (oral corticosteroid or intravenous corticosteroids therapy) within the preceding 1 months
* History of antibiotic use in the previous 1 months
* History of life-threatening asthma
* History of chronic lung diseases other than asthma, including but not limited to chronic obstructive pulmonary disease, bronchiectasis, emphysema, tuberculosis, sarcoidosis, pulmonary fibrosis, lung cancer, etc
* History of serious disease of the heart and cerebrovascular disease
* History of severe liver or renal dysfunction or disease
* History of severe disease in the hematopoietic system
* History of immunodeficiency (including, but not limited to, HIV positive detection, or other acquired or congenital immunodeficiency disease, or organ transplant history)
* History of any other condition (such as known drug or alcohol abuse or psychiatric disorder) which, in the opinion of the investigator, may preclude the patient from following and completing the protocol
* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
* History of allergies to the component of the investigated drugs
* Smoking within the past year
* Contraindication to induced sputum collection method on history or examination
* Any serious medical condition which, in the opinion of the Investigator, would pose a significant risk to the patient or interfere with the interpretation of safety, efficacy, or pharmacodynamic data

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No